Literature DB >> 19066962

Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival.

Jin-Bin Jia1, Peng-Yuan Zhuang, Hui-Chuan Sun, Ju-Bo Zhang, Wei Zhang, Xiao-Dong Zhu, Yu-Quan Xiong, Hua-Xiang Xu, Zhao-You Tang.   

Abstract

PURPOSE: To examine expression profile and prognostic significance of vascular endothelial growth factor (VEGF) and its receptors in hepatocellular carcinoma (HCC) and peritumoral tissue.
METHODS: Expression of VEGF-A, VEGF-C, and VEGF receptor 1(VEGFR-1), VEGFR-2, and VEGFR-3 in tumor and peritumoral liver tissue was studied by immunohistochemistry in a tissue microarray from 107 patients with HCC. Unsupervised hierarchical cluster analyses were conducted to identify relevant clusters.
RESULTS: Staining of VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 was mostly found on the tumor cells and peritumoral hepatocytes, but VEGFR-1 was mostly expressed in stromal cells. In most of the cases, the expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3 in was higher in peritumoral liver tissue, while VEGF-C expression was higher in tumor. Unsupervised hierarchical clustering analysis identified four prognostically different clusters, of which cluster A was classified into the "poor prognosis group," and the other three clusters were classified into the "good prognosis group" (P = 0.047). Further analysis with a set of seven markers reproduced the same four cluster groups with significantly different recurrence free probability (RFP) (P = 0.018), and the low RFP group was associated with more intrahepatic satellite lesions. Multivariate analysis showed that classification defined by seven biomarkers was of prognostic significance (P = 0.000).
CONCLUSIONS: Expression of VEGF and its receptors was higher in peritumoral tissue than in tumor in HCC. Seven biomarkers predicted patients' RFP, which consisted of tumoral expression of VEGF-A, VEGFR-1, and VEGF-C as well as peritumoral expression of VEGF-A, VEGFR-1, VEGFR-2, and VEGFR-3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19066962     DOI: 10.1007/s00432-008-0521-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.

Authors:  X M Li; Z Y Tang; L X Qin; J Zhou; H C Sun
Journal:  J Exp Clin Cancer Res       Date:  1999-12

2.  Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues.

Authors:  R Yamaguchi; H Yano; Y Nakashima; S Ogasawara; K Higaki; J Akiba; D J Hicklin; M Kojiro
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

3.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study.

Authors:  Ronnie Tung-Ping Poon; Irene Oi-Lin Ng; Cecilia Lau; Wun-Ching Yu; Zhen-Fan Yang; Sheung-Tat Fan; John Wong
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

4.  Microvessel density of hepatocellular carcinoma: its relationship with prognosis.

Authors:  H C Sun; Z Y Tang; X M Li; Y N Zhou; B R Sun; Z C Ma
Journal:  J Cancer Res Clin Oncol       Date:  1999-07       Impact factor: 4.553

5.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.

Authors:  Pal Kaposi-Novak; Ju-Seog Lee; Luis Gòmez-Quiroz; Cédric Coulouarn; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

6.  Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.

Authors:  O N El-Assal; A Yamanoi; Y Soda; M Yamaguchi; M Igarashi; A Yamamoto; T Nabika; N Nagasue
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

7.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Peng-Yuan Zhuang; Hong-Guang Zhu; Wei Zhang; Yu-Quan Xiong; Wei-Zhong Wu; Lu Wang; Zhao-You Tang; Hui-Chuan Sun
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

8.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma.

Authors:  R Yamaguchi; H Yano; A Iemura; S Ogasawara; M Haramaki; M Kojiro
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

9.  Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers.

Authors:  N H C Au; M Cheang; D G Huntsman; E Yorida; A Coldman; W M Elliott; G Bebb; J Flint; J English; C B Gilks; H L Grimes
Journal:  J Pathol       Date:  2004-09       Impact factor: 7.996

10.  Protein expression profiling and molecular classification of gastric cancer by the tissue array method.

Authors:  Hye Seung Lee; Sung-Bum Cho; Hee Eun Lee; Min A Kim; Ji Hun Kim; Do Joong Park; Ju Han Kim; Han-Kwang Yang; Byung Lan Lee; Woo Ho Kim
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

View more
  15 in total

1.  Inflammation and cancer.

Authors:  Noemí Eiró; Francisco J Vizoso
Journal:  World J Gastrointest Surg       Date:  2012-03-27

2.  Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model.

Authors:  Jun Qian; Elsie Oppermann; Andreas Tran; Ulli Imlau; Kun Qian; Thomas Josef Vogl
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

4.  VEGFR-1 activation-induced MMP-9-dependent invasion in hepatocellular carcinoma.

Authors:  Tao Li; Yuhua Zhu; Lihui Han; Wanhua Ren; Hui Liu; Chengyong Qin
Journal:  Future Oncol       Date:  2015-11-09       Impact factor: 3.404

5.  High co-expression of vascular endothelial growth factor receptor-1 and Snail is associated with poor prognosis after curative resection of hepatocellular carcinoma.

Authors:  Tao Li; Yuhua Zhu; Wanhua Ren; Shifeng Xu; Zhen Yang; Aiju Fang; Chengyong Qin
Journal:  Med Oncol       Date:  2012-01-15       Impact factor: 3.064

Review 6.  Inflammation and cancer: how friendly is the relationship for cancer patients?

Authors:  Bharat B Aggarwal; Prashasnika Gehlot
Journal:  Curr Opin Pharmacol       Date:  2009-08-06       Impact factor: 5.547

7.  A multidisciplinary approach to the management of hepatocellular carcinoma.

Authors:  Robert G Gish; Jorge A Marrero; Al B Benson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-03

8.  The patterns and expression of KDR in normal tissues of human internal organs.

Authors:  Jianfei Huang; Huijun Zhu; Xudong Wang; Qi Tang; Hua Huang; Kerong Wu; Jin Zhu; Zhenqing Feng; Gongshen Shi
Journal:  J Mol Histol       Date:  2011-09-10       Impact factor: 2.611

9.  High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection.

Authors:  Jin-Bin Jia; Wen-Quan Wang; Hui-Chuan Sun; Xiao-Dong Zhu; Liang Liu; Peng-Yuan Zhuang; Ju-Bo Zhang; Wei Zhang; Hua-Xiang Xu; Ling-Qun Kong; Lu Lu; Wei-Zhong Wu; Lu Wang; Zhao-You Tang
Journal:  Oncologist       Date:  2010-06-15

Review 10.  Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials.

Authors:  Bruna Scaggiante; Maryam Kazemi; Gabriele Pozzato; Barbara Dapas; Rosella Farra; Mario Grassi; Fabrizio Zanconati; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.